目次

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 30)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS AND EXCLUSIONS
1.3 MARKET SCOPE
1.4 YEARS CONSIDERED
1.5 CURRENCY CONSIDERED
1.6 STAKEHOLDERS
1.7 LIMITATIONS
1.8 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 34)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
2.1.2.1 Key data from primary sources
FIGURE 3 KEY INDUSTRY INSIGHTS
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND SIDE): BY TYPE OF BUYER AND REGION
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach one: Revenue mapping-based estimation
FIGURE 6 DIGITAL THERAPEUTICS: REVENUE MAPPING-BASED ESTIMATION
2.2.1.2 Approach two: Buyer adoption-based estimation
FIGURE 7 DIGITAL THERAPEUTICS ESTIMATION: BUYER ADOPTION-BASED ESTIMATION
2.2.2 TOP-DOWN APPROACH: PaENETRATION RATE-BASED MARKET SIZE ESTIMATION
FIGURE 8 PENETRATION RATE-BASED MARKET ESTIMATION
2.2.3 GROWTH FORECAST
TABLE 1 FACTOR ANALYSIS
FIGURE 9 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2022-2027)
FIGURE 10 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 11 DATA TRIANGULATION METHODOLOGY
2.4 ASSUMPTIONS
2.5 RISK ASSESSMENT

3 EXECUTIVE SUMMARY (Page No. - 48)
FIGURE 12 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2022 VS. 2027 (USD MILLION)
FIGURE 13 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, 2022 VS. 2027 (USD MILLION)
FIGURE 14 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, 2022-2027
FIGURE 15 DIGITAL THERAPEUTICS MARKET, BY APPLICATION (2022-2027)
FIGURE 16 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, 2022 VS. 2027 (USD MILLION)
FIGURE 17 GEOGRAPHICAL SNAPSHOT OF DIGITAL THERAPEUTICS MARKET

4 PREMIUM INSIGHTS (Page No. - 53)
4.1 DIGITAL THERAPEUTICS MARKET OVERVIEW
FIGURE 18 INCREASING INCIDENCE OF CHRONIC DISEASES & TECHNOLOGICAL ADVANCEMENTS TO DRIVE ADOPTION OF DIGITAL THERAPEUTICS
4.2 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2022-2027
FIGURE 19 B2B SALES DOMINATE DIGITAL THERAPEUTICS MARKET
4.3 DIGITAL THERAPEUTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 20 NORTH AMERICA TO GROW AT HIGHEST RATE

5 MARKET OVERVIEW (Page No. - 56)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 21 DIGITAL THERAPEUTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of preventable chronic diseases
5.2.1.2 Rising focus on preventive healthcare
5.2.1.3 Need to control healthcare costs
5.2.1.4 Significant increase in venture capital investments
5.2.1.5 Benefits of digital therapeutics
5.2.1.5.1 Ability to induce behavioral change
5.2.1.5.2 Improved drug adherence
5.2.1.5.3 Patient convenience and user-friendliness
5.2.2 RESTRAINTS
5.2.2.1 Patient data privacy concerns
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Large undiagnosed and untreated population
5.2.3.3 Unexplored therapeutic applications
5.2.4 CHALLENGES
5.2.4.1 Unstable payment models
5.2.4.2 Reluctance among patients to adopt digital therapeutics
5.2.4.3 Lack of awareness and access to digital therapeutics programs in developing countries
5.2.4.4 Resistance from traditional healthcare providers
5.3 SUPPLY/VALUE CHAIN ANALYSIS
FIGURE 22 VALUE CHAIN ANALYSIS
5.4 ECOSYSTEM ANALYSIS
FIGURE 23 ECOSYSTEM ANALYSIS
5.5 PIPELINE PRODUCTS
5.6 CASE STUDIES
5.7 PORTER’S FIVE FORCES ANALYSIS
5.7.1 THREAT OF NEW ENTRANTS
5.7.2 BARGAINING POWER OF SUPPLIERS
5.7.3 BARGAINING POWER OF BUYERS
5.7.4 THREAT OF SUBSTITUTES
5.7.5 INTENSITY OF COMPETITIVE RIVALRY
5.8 REGULATORY LANDSCAPE
5.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 2 DIGITAL THERAPEUTICS REGULATORY FRAMEWORK
TABLE 3 DIGITAL THERAPEUTICS MARKET: REGULATORY DATA NEEDED FOR CLASS II DEVICES
5.9 TECHNOLOGY TRENDS
TABLE 4 TECHNOLOGY ENABLERS, BENEFITS, AND EXAMPLES
5.10 INDUSTRY TRENDS
5.10.1 VIRTUAL REALITY
5.10.2 INCREASING DEMAND FOR DIGITAL DELIVERY OF BEHAVIORAL THERAPY
5.10.3 GROWING COLLABORATIONS BETWEEN STAKEHOLDERS
TABLE 5 DIGITAL THERAPEUTICS: RECENT COLLABORATIONS
5.11 PRICING ANALYSIS & REIMBURSEMENT SCENARIO
5.11.1 AVERAGE SELLING PRICE
TABLE 6 DIGITAL THERAPEUTICS PRODUCTS: REIMBURSEMENT & PRICE BY COUNTRY
5.11.2 REIMBURSEMENT SCENARIO
TABLE 7 DIGITAL THERAPEUTICS: GLOBAL COVERAGE DETERMINATION STANDARDS
5.12 PATENT ANALYSIS
5.13 KEY CONFERENCES AND EVENTS IN 2022-2023
TABLE 8 DIGITAL THERAPEUTICS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 24 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL
TABLE 9 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS FOR SALES CHANNEL
5.14.2 BUYING CRITERIA
FIGURE 25 KEY BUYING CRITERIA FOR SALES CHANNEL
TABLE 10 KEY BUYING CRITERIA FOR SALES CHANNEL

6 DIGITAL THERAPEUTICS MARKET, BY APPLICATION (PageNo. - 80)
6.1 INTRODUCTION
TABLE 11 DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
6.2 TREATMENT/CARE-RELATED APPLICATIONS
TABLE 12 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 13 DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
6.2.1 DIABETES
6.2.1.1 Rising prevalence of diabetes to drive market growth
TABLE 14 DIGITAL THERAPEUTICS MARKET FOR DIABETES, BY REGION, 2020-2027 (USD MILLION)
6.2.2 CENTRAL NERVOUS SYSTEM DISORDERS
TABLE 15 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 16 DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY REGION, 2020-2027 (USD MILLION)
6.2.2.1 Mental health disorders
6.2.2.1.1 Benefits of digital therapeutics in managing mental health disorders to drive R&D
TABLE 17 DIGITAL THERAPEUTICS MARKET FOR MENTAL HEALTH DISORDERS, BY REGION, 2020-2027 (USD MILLION)
6.2.2.2 Other CNS disorders
TABLE 18 DIGITAL THERAPEUTICS MARKET FOR OTHER CNS DISORDERS, BY REGION, 2020-2027 (USD MILLION)
6.2.3 SMOKING CESSATION
6.2.3.1 Focus on providing validated, effective mobile applications to help quit smoking to aid market growth
TABLE 19 DIGITAL THERAPEUTICS MARKET FOR SMOKING CESSATION, BY REGION, 2020-2027 (USD MILLION)
6.2.4 CHRONIC RESPIRATORY DISEASES
6.2.4.1 Growing prevalence of COPD and asthma to drive market growth
TABLE 20 DIGITAL THERAPEUTICS MARKET FOR CHRONIC RESPIRATORY DISEASES, BY REGION, 2020-2027 (USD MILLION)
6.2.5 MUSCULOSKELETAL DISORDERS
6.2.5.1 Dearth of physiotherapists to support market growth
TABLE 21 DIGITAL THERAPEUTICS MARKET FOR MUSCULOSKELETAL DISORDERS, BY REGION, 2020-2027 (USD MILLION)
6.2.6 CARDIOVASCULAR DISEASE
6.2.6.1 High burden of CVD to drive demand for digital therapeutics solutions
TABLE 22 DIGITAL THERAPEUTICS MARKET FOR CVD, BY REGION, 2020-2027 (USD MILLION)
6.2.7 MEDICATION ADHERENCE
6.2.7.1 Growing number of medication non-adherence cases to propel market growth
TABLE 23 DIGITAL THERAPEUTICS MARKET FOR MEDICATION ADHERENCE, BY REGION, 2020-2027 (USD MILLION)
6.2.8 GASTROINTESTINAL DISORDERS
6.2.8.1 High prevalence of gastrointestinal disorders to ensure strong interest in developing targeted solutions
TABLE 24 DIGITAL THERAPEUTICS MARKET FOR GASTROINTESTINAL DISORDERS, BY REGION, 2020-2027 (USD MILLION)
6.2.9 REHABILITATION & PATIENT CARE
6.2.9.1 Benefits of digital therapeutics have induced startups to develop platforms for patient care
TABLE 25 DIGITAL THERAPEUTICS MARKET FOR REHABILITATION & PATIENT CARE, BY REGION, 2020-2027 (USD MILLION)
6.2.10 SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT
6.2.10.1 Potential to improve efficiency of behavioral interventions to drive market growth
TABLE 26 DIGITAL THERAPEUTICS MARKET FOR SUBSTANCE USE DISORDERS & ADDICTION MANAGEMENT, BY REGION, 2020-2027 (USD MILLION)
6.2.11 OTHER TREATMENT/CARE-RELATED APPLICATIONS
TABLE 27 DIGITAL THERAPEUTICS MARKET FOR OTHER TREATMENT/CARE-RELATED APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
6.3 PREVENTIVE APPLICATIONS
TABLE 28 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 29 DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)
6.3.1 PREDIABETES
6.3.1.1 Influx of startups to provide effective prevention against prediabetes to support market
TABLE 30 DIGITAL THERAPEUTICS MARKET FOR PREDIABETES, BY REGION, 2020-2027 (USD MILLION)
6.3.2 OBESITY
6.3.2.1 Availability of cost-effective solutions for obesity management to propel market growth
TABLE 31 DIGITAL THERAPEUTICS MARKET FOR OBESITY, BY REGION, 2020-2027 (USD MILLION)
6.3.3 NUTRITION
6.3.3.1 Importance of nutrition in preventing a wide range of ailments to drive demand for digital therapeutic solutions
TABLE 32 DIGITAL THERAPEUTICS MARKET FOR NUTRITION, BY REGION, 2020-2027 (USD MILLION)
6.3.4 LIFESTYLE MANAGEMENT
6.3.4.1 Ability of digital therapeutics solutions to induce positive behavioral changes to contribute to rising demand
TABLE 33 DIGITAL THERAPEUTICS MARKET FOR LIFESTYLE MANAGEMENT, BY REGION, 2020-2027 (USD MILLION)
6.3.5 OTHER PREVENTIVE APPLICATIONS
TABLE 34 DIGITAL THERAPEUTICS MARKET FOR OTHER PREVENTIVE APPLICATIONS, BY REGION, 2020-2027 (USD MILLION)

7 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL (Pae No. - 98)
7.1 INTRODUCTION
TABLE 35 DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
7.2 B2B
TABLE 36 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 37 DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY REGION, 2020-2027 (USD MILLION)
7.2.1 PAYERS
7.2.1.1 Payers to hold largest share of B2B market
TABLE 38 DIGITAL THERAPEUTICS MARKET FOR PAYERS, BY REGION, 2020-2027 (USD MILLION)
7.2.2 EMPLOYERS
7.2.2.1 Rising importance of employee health management to drive adoption of digital therapeutics among employers
TABLE 39 DIGITAL THERAPEUTICS MARKET FOR EMPLOYERS, BY REGION, 2020-2027 (USD MILLION)
7.2.3 PHARMACEUTICAL COMPANIES
7.2.3.1 Growing cross-industry collaborations between digital therapeutics start-ups and pharmaceutical companies to drive market growth
TABLE 40 DIGITAL THERAPEUTICS MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2020-2027 (USD MILLION)
7.2.4 PROVIDERS
7.2.4.1 Potential for better patient management and cost-reduction to drive demand for digital therapeutics among providers
TABLE 41 DIGITAL THERAPEUTICS MARKET FOR PROVIDERS, BY REGION, 2020-2027 (USD MILLION)
7.2.5 OTHER BUYERS
TABLE 42 DIGITAL THERAPEUTICS MARKET FOR OTHER BUYERS, BY REGION, 2020-2027 (USD MILLION)
7.3 B2C
TABLE 43 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 44 DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY REGION, 2020-2027 (USD MILLION)
7.3.1 CAREGIVERS
7.3.1.1 Ease of managing health conditions to drive demand for solutions among caregivers
TABLE 45 DIGITAL THERAPEUTICS MARKET FOR CAREGIVERS, BY REGION, 2020-2027 (USD MILLION)
7.3.2 PATIENTS
7.3.2.1 Awareness of preventive health among patients to support segment growth
TABLE 46 DIGITAL THERAPEUTICS MARKET FOR PATIENTS, BY REGION, 2020-2027 (USD MILLION)

8 DIGITAL THERAPEUTICS MARKET, BY REGION (Page No. 107)
8.1 INTRODUCTION
TABLE 47 DIGITAL THERAPEUTICS MARKET, BY REGION, 2020-2027 (USD MILLION)
8.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET SNAPSHOT
TABLE 48 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 49 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 50 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 51 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 52 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 53 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 54 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 55 NORTH AMERICA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.2.1 US
8.2.1.1 Strong start-up base to ensure high product access for end users
TABLE 56 US: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 57 US: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 58 US: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 59 US: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 60 US: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 61 US: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 62 US: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.2.2 CANADA
8.2.2.1 Government initiatives to support digital therapeutics to drive market growth in Canada
TABLE 63 CANADA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 64 CANADA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 65 CANADA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 66 CANADA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 67 CANADA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 68 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 69 CANADA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.3 EUROPE
FIGURE 27 EUROPE: DIGITAL THERAPEUTICS MARKET SNAPSHOT
TABLE 70 EUROPE: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 71 EUROPE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 72 EUROPE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 73 EUROPE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 74 EUROPE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 75 EUROPE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 76 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 77 EUROPE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.3.1 GERMANY
8.3.1.1 Germany forms largest market for digital therapeutics in Europe due to supportive government initiatives
TABLE 78 GERMANY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 79 GERMANY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 80 GERMANY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 81 GERMANY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 82 GERMANY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 83 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 84 GERMANY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.3.2 UK
8.3.2.1 Well-established healthcare system and government support to propel market
TABLE 85 UK: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 86 UK: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 87 UK: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 88 UK: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 89 UK: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 90 UK: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 91 UK: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.3.3 FRANCE
8.3.3.1 Growing healthcare expenditure and favorable health insurance system to support market
TABLE 92 FRANCE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 93 FRANCE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 94 FRANCE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 95 FRANCE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 96 FRANCE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 97 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 98 FRANCE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.3.4 SPAIN
8.3.4.1 Initiatives by emerging digital therapeutics startups to drive market
TABLE 99 SPAIN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 100 SPAIN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 101 SPAIN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 102 SPAIN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 103 SPAIN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 104 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 105 SPAIN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.3.5 ITALY
8.3.5.1 Need for alternative and effective treatment to drive market
TABLE 106 ITALY: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 107 ITALY: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 108 ITALY: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 109 ITALY: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 110 ITALY: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 111 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 112 ITALY: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.3.6 REST OF EUROPE
TABLE 113 ROE: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 114 ROE: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 115 ROE: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 116 ROE: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 117 ROE: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 118 ROE: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 119 ROE: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.4 ASIA PACIFIC
TABLE 120 APAC: DIGITAL THERAPEUTICS MARKET, BY COUNTRY, 2020-2027 (USD MILLION)
TABLE 121 APAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 122 APAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 123 APAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 124 APAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 125 APAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 126 APAC: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 127 APAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.4.1 JAPAN
8.4.1.1 Rising diabetes incidence and collaborations to drive market growth
TABLE 128 JAPAN: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 129 JAPAN: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 130 JAPAN: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 131 JAPAN: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 132 JAPAN: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 133 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 134 JAPAN: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.4.2 CHINA
8.4.2.1 Growing geriatric population and incidence of chronic conditions to drive demand
TABLE 135 CHINA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 136 CHINA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 137 CHINA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 138 CHINA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 139 CHINA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 140 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 141 CHINA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.4.3 INDIA
8.4.3.1 Rising chronic disease incidence and need for better disease management to drive market
TABLE 142 INDIA: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 143 INDIA: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 144 INDIA: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 145 INDIA: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 146 INDIA: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 147 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 148 INDIA: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.4.4 REST OF ASIA PACIFIC
TABLE 149 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 150 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 151 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 152 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 153 ROAPAC: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 154 ROAPAC DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 155 ROAPAC: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
8.5 REST OF THE WORLD
TABLE 156 ROW: DIGITAL THERAPEUTICS MARKET, BY APPLICATION, 2020-2027 (USD MILLION)
TABLE 157 ROW: DIGITAL THERAPEUTICS MARKET FOR TREATMENT/CARE-RELATED APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 158 ROW: DIGITAL THERAPEUTICS MARKET FOR PREVENTIVE APPLICATIONS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 159 ROW: DIGITAL THERAPEUTICS MARKET FOR CNS DISORDERS, BY TYPE, 2020-2027 (USD MILLION)
TABLE 160 ROW: DIGITAL THERAPEUTICS MARKET, BY SALES CHANNEL, 2020-2027 (USD MILLION)
TABLE 161 ROW: DIGITAL THERAPEUTICS MARKET FOR B2C SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)
TABLE 162 ROW: DIGITAL THERAPEUTICS MARKET FOR B2B SALES CHANNEL, BY BUYER, 2020-2027 (USD MILLION)

9 COMPETITIVE LANDSCAPE (Page No. - 164)
9.1 OVERVIEW
9.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 28 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN DIGITAL THERAPEUTICS
9.3 MARKET SHARE ANALYSIS
TABLE 163 DIGITAL THERAPEUTICS MARKET: DEGREE OF COMPETITION
FIGURE 29 MARKET SHARE ANALYSIS: DIGITAL THERAPEUTICS MARKET
9.4 MARKET RANKING ANALYSIS, 2022
FIGURE 30 DIGITAL THERAPEUTICS MARKET RANKING ANALYSIS, 2022
9.5 COMPETITIVE BENCHMARKING
TABLE 164 DIGITAL THERAPEUTICS MARKET: COMPETITIVE BENCHMARKING OF KEY PLAYERS
TABLE 165 DIGITAL THERAPEUTICS MARKET: SALES CHANNEL FOOTPRINT OF KEY PLAYERS
TABLE 166 DIGITAL THERAPEUTICS MARKET: REGIONAL FOOTPRINT OF KEY PLAYERS
9.5.1 COMPANY EVALUATION MATRIX: DEFINITIONS AND METHODOLOGY
TABLE 167 DIGITAL THERAPEUTICS MARKET: CRITERIA CONSIDERED FOR EVALUATION
9.5.1.1 Stars
9.5.1.2 Emerging leaders
9.5.1.3 Pervasive players
9.5.1.4 Participants
FIGURE 31 DIGITAL THERAPEUTICS MARKET: GLOBAL COMPETITIVE LEADERSHIP MAPPING, 2022
9.5.2 COMPETITIVE LEADERSHIP MAPPING: START-UPS/SMES (2022)
9.5.2.1 Progressive companies
9.5.2.2 Starting blocks
9.5.2.3 Responsive companies
9.5.2.4 Dynamic companies
FIGURE 32 DIGITAL THERAPEUTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES, 2022
9.6 COMPETITIVE SCENARIO
TABLE 168 KEY PRODUCT LAUNCHES AND APPROVALS, JANUARY 2019- AUGUST 2022
9.6.1 DEALS
TABLE 169 DIGITAL THERAPEUTICS MARKET: DEALS, JANUARY 2019 - AUGUST 2022
9.6.2 OTHER DEVELOPMENTS
TABLE 170 DIGITAL THERAPEUTICS MARKET: OTHER DEVELOPMENTS, JANUARY 2019 - AUGUST 2022

10 COMPANY PROFILES (Page No. - 177)
10.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
10.1.1 NOOM
TABLE 171 NOOM: BUSINESS OVERVIEW
10.1.2 TELADOC HEALTH
TABLE 172 TELADOC HEALTH: BUSINESS OVERVIEW
FIGURE 33 TELADOC HEALTH: COMPANY SNAPSHOT (2021)
10.1.3 OMADA HEALTH
TABLE 173 OMADA HEALTH: BUSINESS OVERVIEW
10.1.4 WELLDOC
TABLE 174 WELLDOC: BUSINESS OVERVIEW
10.1.5 PEAR THERAPEUTICS
TABLE 175 PEAR THERAPEUTICS: BUSINESS OVERVIEW
10.1.6 COGNIFIT
TABLE 176 COGNIFIT: BUSINESS OVERVIEW
10.1.7 GINGER
TABLE 177 GINGER: BUSINESS OVERVIEW
10.1.8 PROPELLER HEALTH
TABLE 178 PROPELLER HEALTH: BUSINESS OVERVIEW
10.1.9 2MORROW
TABLE 179 2MORROW: BUSINESS OVERVIEW
10.1.10 CANARY HEALTH
TABLE 180 CANARY HEALTH: BUSINESS OVERVIEW
10.1.11 CLICK THERAPEUTICS
TABLE 181 CLICK THERAPEUTICS: BUSINESS OVERVIEW
10.1.12 AKILI
TABLE 182 AKILI: BUSINESS OVERVIEW
10.1.13 WELLTHY THERAPEUTICS
TABLE 183 WELLTHY THERAPEUTICS: BUSINESS OVERVIEW
10.1.14 COGNOA
TABLE 184 COGNOA: BUSINESS OVERVIEW
10.1.15 TWILL
TABLE 185 TWILL: BUSINESS OVERVIEW
10.1.16 KAIA HEALTH
TABLE 186 KAIA HEALTH: BUSINESS OVERVIEW
10.1.17 BETTER THERAPEUTICS
TABLE 187 BETTER THERAPEUTICS: BUSINESS OVERVIEW
10.1.18 MINDSTRONG HEALTH
TABLE 188 MINDSTRONG HEALTH: BUSINESS OVERVIEW
10.1.19 BEHAVR
TABLE 189 BEHAVR: BUSINESS OVERVIEW
10.1.20 AYOGO
TABLE 190 AYOGO: BUSINESS OVERVIEW
10.2 OTHER PLAYERS
10.2.1 MINDABLE HEALTH
10.2.2 VIRTA HEALTH CORP
10.2.3 HINGE HEALTH
10.2.4 OREXO AB
10.2.5 FREESPIRA

*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.

11 APPENDIX (Page No. - 224)
11.1 DISCUSSION GUIDE
11.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
11.3 CUSTOMIZATION OPTIONS
11.4 RELATED REPORTS
11.5 AUTHOR DETAILS